Latest Pharmaceuticals News

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

Bioxyne Limited has reported a remarkable 77% jump in revenue for Q2 FY2025, alongside positive operating cash flow, as it prepares to expand manufacturing capacity and enter new international markets.

Clarity Pharmaceuticals will present compelling data on its 64Cu-SAR-bisPSMA diagnostic agent at two leading oncology conferences, highlighting earlier and more accurate prostate cancer lesion detection than current standards.

IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.

IDT Australia has finalized a $20 million asset-based loan facility with ScotPac, replacing its previous $4.7 million NAB facility, to support its expanding sales pipeline and recent contract wins.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.